Literature DB >> 6124807

Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.

N Quinn, C D Marsden, J D Parkes.   

Abstract

The cause(s) of response fluctuations in patients with Parkinson's disease treated chronically with levodopa is unknown. In some subjects it is difficult to establish a clear relation between levodopa dosage and timing and the resultant clinical effects. This may be due to variation in the degree of absorption of the drug, and in the latency from ingestion to peak plasma level and from plasma peak to central action. In one patient illustrated, careful analysis of "on-off" charts reveals an underlying pattern of end-of-dose deterioration at a time when history alone suggested a completely random response to levodopa. In three patients replacement of oral treatment by continuous intravenous infusion of levodopa, with oral administration of decarboxylase inhibitor, produced a prolonged and stable clinical response, even when ambulant. This response was maintained not only in one subject showing predictable fluctuations, but also in two subjects with unpredictable response to oral treatment. The addition of intravenous levodopa infusion to the usual oral regimen of the first patient when she was experiencing prolonged "off" periods despite generous doses of oral levodopa with decarboxylase inhibitor also produced stable clinical benefit. These results suggest that, even in patients with complicated response swings, central dopamine receptors remain available for stimulation providing levodopa can be delivered at a constant rate and in an adequate quantity to the brain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124807     DOI: 10.1016/s0140-6736(82)90442-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 2.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 3.  Parkinson's disease.

Authors:  E C Wolters; D B Calne
Journal:  CMAJ       Date:  1989-03-01       Impact factor: 8.262

4.  Multicenter trial of L-Deprenyl in Parkinson disease.

Authors:  S Ruggieri; A Denaro; G Meco; A Carta; F Stocchi; A Agnoli
Journal:  Ital J Neurol Sci       Date:  1986-02

5.  Madopar HBS and the decompensated phase of Parkinson disease.

Authors:  T Caraceni; N Nordera; E Lamperti; A Lorizio
Journal:  Ital J Neurol Sci       Date:  1989-08

Review 6.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 7.  The striatal cholinergic system in L-dopa-induced dyskinesias.

Authors:  X A Perez; T Bordia; M Quik
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

Review 8.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

9.  "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.

Authors:  T Eriksson; T Magnusson; A Carlsson; A Linde; A K Granérus
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.